全文获取类型
收费全文 | 158778篇 |
免费 | 12428篇 |
国内免费 | 6914篇 |
专业分类
耳鼻咽喉 | 581篇 |
儿科学 | 2919篇 |
妇产科学 | 1807篇 |
基础医学 | 26461篇 |
口腔科学 | 2428篇 |
临床医学 | 12706篇 |
内科学 | 31459篇 |
皮肤病学 | 2214篇 |
神经病学 | 11038篇 |
特种医学 | 2731篇 |
外国民族医学 | 29篇 |
外科学 | 9225篇 |
综合类 | 25116篇 |
预防医学 | 10195篇 |
眼科学 | 1522篇 |
药学 | 20511篇 |
30篇 | |
中国医学 | 6051篇 |
肿瘤学 | 11097篇 |
出版年
2023年 | 1708篇 |
2022年 | 2832篇 |
2021年 | 4846篇 |
2020年 | 4767篇 |
2019年 | 4454篇 |
2018年 | 4243篇 |
2017年 | 4805篇 |
2016年 | 5219篇 |
2015年 | 6011篇 |
2014年 | 10063篇 |
2013年 | 11222篇 |
2012年 | 10572篇 |
2011年 | 11625篇 |
2010年 | 9339篇 |
2009年 | 9024篇 |
2008年 | 9206篇 |
2007年 | 8867篇 |
2006年 | 8008篇 |
2005年 | 7210篇 |
2004年 | 5982篇 |
2003年 | 5128篇 |
2002年 | 4046篇 |
2001年 | 3493篇 |
2000年 | 2894篇 |
1999年 | 2414篇 |
1998年 | 2073篇 |
1997年 | 1829篇 |
1996年 | 1450篇 |
1995年 | 1533篇 |
1994年 | 1383篇 |
1993年 | 1144篇 |
1992年 | 1015篇 |
1991年 | 892篇 |
1990年 | 772篇 |
1989年 | 658篇 |
1988年 | 590篇 |
1987年 | 520篇 |
1986年 | 460篇 |
1985年 | 864篇 |
1984年 | 829篇 |
1983年 | 617篇 |
1982年 | 652篇 |
1981年 | 530篇 |
1980年 | 474篇 |
1979年 | 380篇 |
1978年 | 308篇 |
1977年 | 249篇 |
1976年 | 255篇 |
1975年 | 215篇 |
1974年 | 172篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
1.
A molecular perspective for the use of type IV tyrosine kinase inhibitors as anticancer therapeutics
《Drug discovery today》2022,27(3):808-821
Tyrosine kinases are enzymes that can transfer a phosphate group from ATP to a specific protein tyrosine, serine or threonine residue within a cell, operating as a switch that can turn ‘on’ and ‘off’ causing different physiological alterations in the body. Mutated kinases have been shown to display an equilibrium shift toward the activated state. Types I–III have been studied intensively leading to drugs like imatinib (type II), cobimetinib (type III), among others. It is the same scenario for types V–VII; however, there is a lacuna in information regarding type IV inhibitors, although recently some advances have surfaced. This review aims to accumulate the knowledge gained so far about type IV inhibitors. 相似文献
2.
3.
Bipul Gnyawali Antoinette Pusateri Ashley Nickerson Sajid Jalil Khalid Mumtaz 《World journal of gastroenterology : WJG》2022,28(29):3793-3802
Chronic Hepatitis B is a highly prevalent disease worldwide and is estimated to cause more than 800000 annual deaths from complications such as cirrhosis and hepatocellular carcinoma (HCC). Although universal hepatitis B vaccination programs may have reduced the incidence and prevalence of chronic hepatitis B and related HCC, the disease still imposes a significant healthcare burden in many endemic regions such as Africa and the Asia-Pacific region. This is especially concerning given the global underdiagnosis of hepatitis B and the limited availability of vaccination, screening, and treatment in low-resource regions. Demographics including male gender, older age, ethnicity, and geo graphic location as well as low socioeconomic status are more heavily impacted by chronic hepatitis B and related HCC. Methods to mitigate this impact include increasing screening in high-risk groups according to national guidelines, increasing awareness and health literacy in vulnerable populations, and developing more robust vaccination programs in under-served regions. 相似文献
4.
5.
6.
《Vaccine》2022,40(19):2679-2695
Vaccinations are essential for preventing infectious diseases in children with chronic diseases as they have increased risk of infection from frequent use of biologics. Response to immunizations in this group is not well known.ObjectiveA systematic review was performed to evaluate three primary outcomes: efficacy; immunogenicity; and safety of vaccines in children with chronic conditions treated with biologics.MethodsThe protocol for our systematic review and meta-analysis was registered and published with PROSPERO. We searched electronic bibliographic databases for studies published from 2009 to 2019, focusing on vaccinations in children with chronic conditions treated with biologics.ResultsWe retrieved 532 records. Thirty-one full-text articles were selected, and 14 were included in the meta-analysis. No significant publication bias was found. Efficacy: limited data are available regarding the efficacy of vaccination, as most studies have focused on immunogenicity as surrogate outcome for efficacy. Immunogenicity: patients receiving anti-TNF-alpha therapy had a statistically significant risk of poor seroconversion (p = 0.028) and seroprotection by the serotype B influenza vaccine [inflammatory bowel disease (IBD) p = 0.013; juvenile idiopathic arthritis (JIA) p = 0.004]. We found adequate responses with H1N1 and H3N2 serotypes. Few studies existed for pneumococcal, hepatitis A virus, hepatitis B virus, varicella-zoster virus, Measles Mumps Rubella virus, and multiple vaccine administration. Safety: vaccine administration was not associated with serious side effects, but JIA patients on anti-TNF alpha therapy had a statistically significant risk of presenting with myalgia or arthralgia postinfluenza vaccine (p = 0.014).ConclusionsMore evidence concerning efficacy, immunogenicity, and safety of vaccinations is needed to guide physicians in the vaccine decision process for this pediatric population. 相似文献
7.
地鳖中的纤溶活性蛋白是从地鳖中提取的具有抗栓及抗肿瘤作用的有效成分,其口服易被上消化道酶分解从而限制了应用。采用恒流泵滴制法开发地鳖纤溶活性蛋白时间/pH依赖口服结肠靶向微囊(EnpolypHaga fibrinolytic protein oral colon targeting microcapsules, CTM-EFP)。采用单因素实验和正交实验相结合的方法寻找到包封率为60.17 % ± 2.72 %、载药量为15.50 % ± 0.44 % 的最佳配方。扫描电子显微镜(SEM)显示微囊呈球形、表面光滑,在人工肠液中24 h的累积释放度为99.53 % ± 0.69 %,在人工胃液中24 h累积释放度为7.43 ± 1.04 %,通过时间/pH依赖达到结肠靶向作用。CTM-EFP在人工肠液中的体外释放曲线符合Korsmeyer方程,提示地鳖纤溶活性蛋白(EnpolypHaga fibrinolytic protein, EFP)是通过扩散和侵蚀机制结合释放的。CTM-EFP为EFP的口服给药提供了一种新的剂型,为EFP应用于临床提供参考。 相似文献
8.
目的:探讨赣南地区原发性肺鳞癌患者EGFR和ALK基因突变的特点,科学指导此类患者优选靶向用药。方法:入组73例原发性肺鳞癌病例,采用ARMS-PNA技术检测EGFR基因第18、19、20、21外显子突变,应用不平衡法检测其中60例病例的ALK融合基因,回顾性分析EGFR和ALK基因突变患者的临床病理特征。结果:EGFR基因突变8例,阳性率为10.96%(8/73),4例为L858R突变,3例为19del突变,1例为G719X突变。女性患者突变率(66.67%,2/3)明显高于男性患者(8.57%,6/70)(P=0.030),EGFR基因突变在高龄(≥60岁)、进展期(N_(1-3)、Ⅲ+Ⅳ期)患者中相对较高,但差异无统计学意义(P>0.05)。EGFR基因突变与吸烟史、T分期以及肿瘤分布位置均无相关性(P>0.05);ALK融合基因表达2例,阳性率3.33%(2/60),与患者性别、年龄、吸烟史、TNM分期及肿瘤分布类型等各临床病理特征均无相关性(P>0.05);未发现EGFR和ALK基因共存突变病例。结论:赣南地区原发性肺鳞癌患者EGFR和ALK基因突变率相对不高,EGFR基因突变以L858R和19del突变为主,且好发于女性患者,可能是患者病情进展的预测因子之一。 相似文献
9.
《Vaccine》2022,40(32):4296-4300
Advanced computational methodologies suggested SARS-CoV-2, nonstructural proteins ORF1AB, ORF3a, as the source of immunodominant peptides for T cell presentation. T cell immunity is long-lasting and compatible with COVID-19 pathology. Based on the supporting clinical data, nonstructural SARS-CoV-2 protein vaccines could provide global immunity against COVID-19. 相似文献
10.